|
1) Yeung EW, Whitehead NP, Suchyna TM, et al. Effects of stretch-activated channel blockers on [Ca2＋]i and muscle damage in the mdx mouse. J Physiol. 2005; 562: 367-80
|
|
|
|
2) Wilton SD, Dye DE, Blechynden LM, et al. Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy？ Neuromuscul Disord. 1997; 7: 329-35
|
|
|
|
|
3) Crawford GE, Lu QL, Partridge TA, et al. Suppression of revertant fibers in mdx mice by expression of a functional dystrophin. Hum Mol Genet. 2001; 10: 2745-50
|
|
|
|
|
|
4) Lu QL, Morris GE, Wilton SD, et al. Massive idiosyncratic exon skipping corrects the nonsese mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol. 2000; 148: 985-96
|
|
|
|
|
|
5) Yokota T, Lu QL, Morgan JE, et al. Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J Cell Sci. 2006; 119: 2679-87
|
|
|
|
|
|
6) Wilton SD, Fletcher S. Modification of pre-mRNA processing: application to dystrophin expression. Curr Opin Mol Ther. 2006; 8: 130-5
|
|
|
|
|
|
7) Wells DJ. Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy. J Muscle Res Cell Motil. 2006; 27: 387-98
|
|
|
|
|
|
8) Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med. 2006; 12: 175-7
|
|
|
|
|
|
9) Aartsma-Rus A, JansoN AA, Kaman WE, et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet. 2004; 74: 83-92
|
|
|
|
|
|
10) Melis MA, Cau M, Muntoni F, et al. Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol. 1998; 2: 255-61
|
|
|
|
|
|
11) Schwartz M, Duno M, Palle AL, et al. Deletion of exon 16 of the dystrophin gene is not associated with disease. Hum Mutat. 2007; 28: 205
|
|
|
|
|
|
12) Wilson C, Keefe AD. Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol. 2006; 10: 607-4
|
|
|
|
|
|
13) Karkare S, Bhatnagar D. Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino. Appl Microbiol Biotechnol. 2006; 71: 575-86
|
|
|
|
|
|
14) Lu QL, Rabinowitz A, Chen YC, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A. 2005; 102: 198-203
|
|
|
|
|
|
15) Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding: nonsense exonic mutations that affect splicing. Nat Rev Genet. 2002; 3: 285-98
|
|
|
|
|
|
16) Lu QL MC, Lou F, Bou-Gharios G, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med. 2003; 9: 1009 -14
|
|
|
|
|
|
17) Wee KB, Pramono ZA, Wang JL, et al. Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides. PloS ONE. 2008; 26: e1884
|
|
|
|
|
|
18) Artsma-Rus A, Janson AA, Kaman WE, et al. Therapeutic sntisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet. 2003; 12: 907-14
|
|
|
|
|
|
19) Arechavala-Gomeza V, Graham LR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther. 2007; 18: 798-810
|
|
|
|
|
|
20) Grounds MD, Radley HG, Lynch GS, et al. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008; 31: 1-19
|
|
|
|
|
|
21) Wells KE, Flrcher S, Mann CJ, et al. Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Lett. 2003; 552: 145-9
|
|
|
|
|
|
22) Fletcher S, Honeyman K, Fall AM, et a. Dystrophin expression in the mdx mouse after localized and systemic administration of a morpholino antisense oligonucleotide. J Gene Med. 2006; 8: 207-16
|
|
|
|
|
|
23) Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther. 2008; 16: 1624-9
|
|
|
|
|
|
24) Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science. 2004; 306: 1796-9
|
|
|
|
|
|
25) Shimatsu Y, Katagiri K, Furuta T, et al. Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim. 2003; 52: 93-7
|
|
|
|
|
26) Shimatsu Y, Yoshimura M, Yuasa K, et al. Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol. 2005; 24: 145-54
|
|
|
|
|
|
27) Yugeta N, Urasawa N, Fujii Y, et al. Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovascular Disord. 2006; 6: 47
|
|
|
|
|
|
28) Urasawa N, Wada MR, Machida N, et al. Selective vacuolar degeneration in dystrophin-deficient canine Purkinje fibers despite preservation of dystrophin-associated proteins with overexpression of Dp71. Circulation. 2008; 117: 2437-48
|
|
|
|
|
|
29) McClorey G, Moulton HM, Iversen PL, et al. Antisense oligonucleotideinduced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 2006; 13: 1373-81
|
|
|
|
|
|
30) Araki E, Nakamura K, Nakao K, et al. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem Biophys Res Commun. 1997; 238: 492-7
|
|
|
|
|
|
31) van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357: 2677-86
|
|
|
|
|
|
32) Kameya S, Araki E, Katsuki M, et al. Dp260 disrupted mice revealed prolonged implicit time of the b-wave in ERG and loss of accumulation of beta-dystroglycan in the outer plexiform layer of the retina. Hum Mol Genet. 1997; 6: 2195-203
|
|
|
|
|
|
33) Muntoni F, Bushby K, van Ommen G. 128th ENMC International Workshop on 'Preclinical optimization and Phase I/II clinical trials using antisense oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands. Neuromuscul Disord. 2005; 15: 450-7
|
|
|
|
|
|
34) Yokota T, Pistilli E, Duddy W, et al. Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2007; 7: 831-42
|
|
|
|
|
|
35) Nakamura A, Yoshida K, Fukushima K, et al. Follow-up of three cases with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) Gene. J Clin Neurosci. 2008; 15: 757-63
|
|
|
|
|
|
36) Beroud C, Tuffery-Giraud S, Matsuo M, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat. 2007; 28: 196-202
|
|
|
|
|
|
37) Wang X, Liang HD, Dong B, et al. Gene transfer with microbubble ultrasound and plasmid DNA into skeletal muscle of mice: comparison between commercially available microbubble contrast agents. Radiology. 2005; 237: 224-9
|
|
|
|
|
|
38) Aartsma-Rus A, van Ommen GJ. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA. 2007; 13: 1609-24
|
|
|
|
|